Arbutin 7% + Tranexamic Acid 4% Cream

Aurelle Melasma Recovery Cream is a topical brightening treatment formulated specifically for melasma and hormonally driven hyperpigmentation, rather than for sun-induced age spots or post-inflammatory marks. It is intended for adults experiencing symmetrical facial pigmentation that appeared following pregnancy, hormonal contraceptive use, or perimenopause. The formula combines four active ingredients that address pigment formation through different mechanisms. Alpha-Arbutin at 7% inhibits tyrosinase, the enzyme responsible for melanin synthesis. Tranexamic Acid at 4% interrupts the plasmin-mediated pathway associated with hormonally triggered pigmentation, which single-active brightening creams typically do not target. Niacinamide limits the transfer of melanosomes from melanocytes to surrounding skin cells and supports barrier function. Glutathione contributes antioxidant activity. This multi-pathway approach reflects the clinical understanding that melasma forms through several simultaneous processes, which is why formulas built around a single brightener often produce partial or temporary results. The cream contains no hydroquinone, no retinoids, no added fragrance and no essential oils. These exclusions matter for two groups in particular: individuals with reactive or sensitive skin, and those with Fitzpatrick skin types IV to VI, for whom irritation from harsh actives can trigger post-inflammatory hyperpigmentation that worsens the original concern. Alpha-Arbutin is not an exfoliating acid and does not compromise the skin barrier, which allows twice-daily application. Application is morning and night on clean, dry skin, using approximately a pea-sized amount pressed gently over pigmented areas and then across the face. Rubbing is discouraged, as friction can aggravate melasma-prone skin. Daily broad-spectrum sun protection is required alongside the cream; ultraviolet and visible light reactivate the melanocytes the formula is working to calm, and without sun protection, fading and re-darkening occur in parallel. Typical timelines reported by users: newer patches begin to lighten around weeks three to four; visible change is generally apparent in photographs by weeks six to eight; deeper or long-established patches may require eight to ten weeks or longer. One tube provides approximately eight weeks of twice-daily facial application. Melasma is a chronic condition with a hormonal component. No topical product, including prescription treatments, eliminates the underlying tendency. Continued application combined with daily sun protection is what maintains results once achieved. The product is a cosmetic intended for topical use. It is not a drug and is not intended to diagnose, treat, cure or prevent any disease. Individuals who are pregnant, breastfeeding, taking prescription medication, or under dermatological care should consult a physician before use. A patch test is recommended before first application. Aurelle is sold exclusively at aurelleskin.com.